Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era.

Bedognetti D, Zoppoli G, Sertoli MR, Zanardi E, Blandini P, Uccellini L, Boccardo F, Andreoli GB, Ghio R, Racchi O, Ferrarini M, De Maria A.

Int J Hematol. 2010 Mar;91(2):342-4; author reply 345-6. doi: 10.1007/s12185-010-0522-z. Epub 2010 Feb 27. No abstract available.

PMID:
20191334
2.

Improving testing for hepatitis B before treatment with rituximab.

Dyson JK, Jopson L, Ng S, Lowery M, Harwood J, Waugh S, Valappil M, McPherson S.

Eur J Gastroenterol Hepatol. 2016 Oct;28(10):1172-8. doi: 10.1097/MEG.0000000000000689.

3.

Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.

Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST.

Ann Hematol. 2011 Oct;90(10):1219-23. doi: 10.1007/s00277-011-1241-0. Epub 2011 Apr 26.

PMID:
21520001
4.

A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience.

Oh MJ, Lee HJ.

Clin Mol Hepatol. 2013 Mar;19(1):51-9. doi: 10.3350/cmh.2013.19.1.51. Epub 2013 Mar 25.

5.

Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.

Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lie AK, Lai CL, Kwong YL, Yuen MF.

J Clin Oncol. 2014 Nov 20;32(33):3736-43. doi: 10.1200/JCO.2014.56.7081. Epub 2014 Oct 6.

PMID:
25287829
6.

Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.

Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M.

BMC Gastroenterol. 2014 Feb 17;14:31. doi: 10.1186/1471-230X-14-31.

7.

Prospective evaluation of seropositive occult hepatitis B viral infection in lymphoma patients receiving chemotherapy.

Cheung WI, Lin SY, Leung VK, Fung KS, Lam YK, Lo FH, Chau TN.

Hong Kong Med J. 2011 Oct;17(5):376-80.

8.

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.

Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS.

Eur J Cancer. 2013 Nov;49(16):3486-96. doi: 10.1016/j.ejca.2013.07.006. Epub 2013 Aug 1.

PMID:
23910494
9.

Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.

Borentain P, Colson P, Coso D, Bories E, Charbonnier A, Stoppa AM, Auran T, Loundou A, Motte A, Ressiot E, Norguet E, Chabannon C, Bouabdallah R, Tamalet C, GĂ©rolami R.

J Viral Hepat. 2010 Nov;17(11):807-15. doi: 10.1111/j.1365-2893.2009.01239.x.

PMID:
20002298
10.

High Frequency of Hepatitis B Core and Surface Antibodies in Hepatitis C Virus-Infected Patients on the Screening Examination.

Suto C, Murakami H, Kobayashi Y, Nagamine T, Saitoh T, Kasamatsu T, Ogawara H, Murakami M.

Rinsho Byori. 2015 Mar;63(3):305-11.

PMID:
26524852
11.
12.

Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis.

Zhang B, Wang J, Xu W, Wang L, Ni W.

Onkologie. 2010;33(10):537-9. doi: 10.1159/000319696. Epub 2010 Sep 10.

PMID:
20926902
13.

High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.

Cho Y, Yu SJ, Cho EJ, Lee JH, Kim TM, Heo DS, Kim YJ, Yoon JH.

J Med Virol. 2016 Jun;88(6):1010-7. doi: 10.1002/jmv.24423. Epub 2015 Nov 13.

PMID:
26531242
14.

Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma.

Guarino M, Picardi M, Vitello A, Pugliese N, Rea M, Cossiga V, Pane F, Caporaso N, Morisco F.

Ann Hepatol. 2017 March-April;16(2):198-206. doi: 10.5604/16652681.1231567.

15.

Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.

Kusumoto S, Tanaka Y, Ueda R, Mizokami M.

J Gastroenterol. 2011 Jan;46(1):9-16. doi: 10.1007/s00535-010-0331-4. Epub 2010 Oct 6. Review.

PMID:
20924616
16.

Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection.

Kami M, Hamaki T, Murashige N, Kishi Y, Kusumi E, Yuji K, Miyakoshi S, Ueyama J, Morinaga S, Mutou Y.

Hematol J. 2003;4(2):159-62. No abstract available.

PMID:
12750737
17.

Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.

Mozessohn L, Chan KK, Feld JJ, Hicks LK.

J Viral Hepat. 2015 Oct;22(10):842-9. doi: 10.1111/jvh.12402. Epub 2015 Mar 13. Review.

PMID:
25765930
18.

Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.

Papadopoulos N, Deutsch M, Manolakopoulos S, Bitsi C, Michalakeas H, Poulakidas H, Tsironi E, Giannouli S, Papatheodoridis GV, Koskinas J, Pectasides D.

Eur J Gastroenterol Hepatol. 2017 Jan;29(1):56-60.

PMID:
27669175
19.

Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection.

Watanabe M, Shibuya A, Tsunoda Y, Danbara M, Ishii R, Ohsaka M, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Horie R, Higashihara M, Koizumi W.

Liver Int. 2011 Mar;31(3):340-7. doi: 10.1111/j.1478-3231.2010.02417.x. Epub 2010 Dec 7.

PMID:
21134110
20.

Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance.

Yang JD, Girotra M, Restrepo A, Waheed S, Barlogie B, Duarte-Rojo A.

Ann Hepatol. 2014 Jul-Aug;13(4):461-5.

Supplemental Content

Support Center